Trinity Biotech Collaborates to Enhance Prostate Cancer Test

The latest announcement is out from Trinity Biotech ( (TRIB) ).

On November 14, 2025, Trinity Biotech announced a strategic collaboration with a leading bioinformatics company to enhance the EpiCapture prostate cancer test through advanced epigenetic analysis. This collaboration aims to improve the test’s ability to monitor prostate cancer progression non-invasively, potentially reducing the need for invasive procedures and improving patient care. The EpiCapture test, currently in late-stage development, has shown promise in accurately predicting high-grade cancers and is part of Trinity Biotech’s strategy to expand its portfolio of innovative diagnostic technologies.

The most recent analyst rating on (TRIB) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Trinity Biotech stock, see the TRIB Stock Forecast page.

Spark’s Take on TRIB Stock

According to Spark, TipRanks’ AI Analyst, TRIB is a Underperform.

Trinity Biotech’s overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and profitability, high debt levels, and negative equity. Technical analysis indicates bearish momentum, further weighing on the stock’s outlook. The negative P/E ratio and lack of dividend yield contribute to a poor valuation score, reinforcing the need for strategic improvements to enhance financial stability and investor confidence.

To see Spark’s full report on TRIB stock, click here.

More about Trinity Biotech

Trinity Biotech is a commercial-stage biotechnology company specializing in diabetes management solutions and human diagnostics, including wearable biosensors. The company develops and markets diagnostic systems for point-of-care and clinical laboratory segments, and has recently expanded into the wearable biosensor industry. Its products are used to detect infectious diseases and measure various chemistry parameters in blood, and it operates in over 75 countries worldwide.

Average Trading Volume: 842,373

Technical Sentiment Signal: Strong Sell

Current Market Cap: $15.87M

For a thorough assessment of TRIB stock, go to TipRanks’ Stock Analysis page.